The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Origin Materials, Inc. (ORGN)
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz reminds investors of the upcoming October 24, 2023 deadline to file a lead plaintiff motion... Read more.
1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and Immunology Expertise
SAN DIEGO–(BUSINESS WIRE)–1859, an AI-driven small molecule drug discovery company advancing next-generation medicines, is pleased to announce the appointment... Read more.
JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests
Geneoscopy’s noninvasive, multi-target, stool RNA (mt-sRNA) colorectal cancer screening test showed extraordinary sensitivity for detecting early-stage (Stage... Read more.
Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor (TKI) at the European Society for Clinical Oncology (ESMO) Congress
BEIJING–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd. (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision... Read more.
Quectel Expands Its IoT Antenna Portfolio With Six New 4G and 5G Antennas
VANCOUVER, British Columbia–(BUSINESS WIRE)–Quectel, a global IoT solutions provider, has unveiled six new antennas designed to provide robust connectivity... Read more.
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with... Read more.
SIMO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Silicon Motion Technology Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK–(BUSINESS WIRE)–$SIMO #classaction–Attorney Advertising– Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm,... Read more.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
AstraZeneca and Daiichi Sankyo’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial... Read more.
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial... Read more.
Wandke Consulting Rebrands as Wandke Accessibility
Innovative disability-owned agency specializing in helping companies create accessible services, platforms, and environments unveils new website logo and client... Read more.